A 24-Week Study of the Efficacy and Safety of Teduglutide in Subjects With Parenteral Nutrition-Dependent Short Bowel Syndrome

Trial Profile

A 24-Week Study of the Efficacy and Safety of Teduglutide in Subjects With Parenteral Nutrition-Dependent Short Bowel Syndrome

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Nov 2017

At a glance

  • Drugs Teduglutide (Primary)
  • Indications Short bowel syndrome
  • Focus Registrational; Therapeutic Use
  • Acronyms STEPS
  • Sponsors NPS Pharmaceuticals
  • Most Recent Events

    • 22 Nov 2017 Results of post hoc analysis assessing the factors associated with response to teduglutide in patients with short-bowel syndrome and intestinal failure, were published in the Gastroenterology.
    • 01 Nov 2017 Results of post-hoc analysis assessing baseline characteristics and clinical response to teduglutide presented at the 25th United European Gastroenterology Week
    • 01 Nov 2017 Results of post-hoc analysis assessing effect of teduglutide on fluid composite presented at the 25th United European Gastroenterology Week
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top